Saturday 17 October 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,125.0%, EPS fell 66.7% and free cash flow fell 67.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
59.79
2.07
−3.35%
Follow CGON
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 3 | — | — |
+8 more TTM periods Free account |
| (26.41%) | (20.79%) | (21.67%) | (24.74%) | ||
| (25.11%) | (20.04%) | (20.82%) | (23.63%) | ||
ROIC |
(4,111.64%) | (724.76%) | (886.69%) | (1,084.56%) | |
Return on Tangible Assets |
(22.06%) | (17.26%) | (21.63%) | (22.26%) | |
Average Days of Receivables |
24.44 | 90.84 | 55.85 | 84.79 | |
Free Cash Flow per Share |
(2.03) | (1.90) | (1.71) | (1.53) | |
Free Cash Flow |
(179.34) | (160.43) | (132.48) | (117.13) | |
Capital Expenditures |
(0.88) | (0.42) | (0.13) | (0.34) | |
| Other line items | |||||
Cash ROIC |
(8.70%) | (7.39%) | (8.85%) | (8.54%) | |
Accounts Receivable Turnover |
12.72 | 6.32 | 6.12 | 6.80 | |
Accounts Payable Turnover |
1.16 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
402.75 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
31.74 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2,508.51% | 2,594.26% | 2,594.33% | 5,118.72% | |
Selling, General and Administrative Expense of Revenue |
1,462.48% | 1,552.16% | 1,635.36% | 3,032.84% | |
Share Based Compensation of Revenue |
567.21% | 546.54% | 593.33% | 1,104.15% | |
Operating CF/Net income |
0.80 | 0.86 | 0.82 | 0.77 | |
Depreciation/Fixed assets |
0.13 | 0.21 | 0.03 | (0.01) | |
Capex/Depreciation |
(0.45) | (0.13) | (0.31) | 2.95 | |
Revenue per Share |
0.07 | 0.06 | 0.06 | 0.03 | |
Operating CF per Share |
(2.02) | (1.89) | (1.71) | (1.52) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.14 | 0.08 | 0.03 | 0.15 |
Columns are period end dates